Lv6
2080 积分 2024-02-20 加入
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
22小时前
已完结
Non-invasive tests for evaluating treatment response in NAFLD
22小时前
已完结
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis
3天前
已完结
Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery
5天前
已完结
Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor
1个月前
已完结
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
1个月前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1个月前
已完结
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study
1个月前
已完结
COURVOISIER'S LAW
2个月前
已完结
Giant pseudosarcomatous polyp of the gallbladder
2个月前
已完结
皖公网安备34019202002308
